PeerJ · 2026
Correlations between inflammatory biomarkers and clinicopathological features in surgically resected thymic epithelial tumors: implications for preoperative diagnosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fu Jun, Han Peng, Xu Jiahang, Deng Wanjun, Chen Baojun, Liu Yong
Аннотация
OBJECTIVE: This study aimed to analyze the correlations between pathological characteristics, risk factors, and inflammatory biomarkers in patients with thymic epithelial tumors (TETs) undergoing surgical resection.
METHODS: A retrospective cohort of adult patients with histopathologically confirmed TETs undergoing radical resection between 2015 and 2024 was analyzed. The Kruskal-Wallis test was employed to evaluate associations of systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR) with clinical features (age; gender; myasthenia gravis (MG); World Health Organization (WHO) stage; tumor size; Masaoka stage; WHOMScore). A nomogram diagnostic model was constructed to differentiate thymoma from thymic carcinoma.
RESULTS: A total of 111 patients (52 males, 59 females) were enrolled, including eight cases of type A thymoma, 38 type AB, nine type B1, 16 type B2, 12 type B3, and 28 thymic carcinomas. Correlations between SII, NLR, PLR, and clinicopathological features (gender, age, MG, tumor size, risk stratification, Masaoka stage, and WHO classification) were analyzed. Significant differences in SII, NLR, and PLR were observed across WHO classifications (P SII < 0.001; P NLR < 0.001; P PLR = 0.004). Dunn's test further revealed that these differences primarily stemmed from distinctions between thymoma and thymic carcinoma groups. Based on PLR and MG status, a combined diagnostic model was developed, which demonstrated favorable performance in differentiating thymoma from thymic carcinoma (AUC = 0.804).
CONCLUSION: Our findings suggest that inflammatory biomarkers (SII, NLR, and PLR) are significantly associated with the malignancy of TETs. The combination of PLR and MG status may serve as a useful auxiliary tool for distinguishing thymoma from thymic carcinoma, showing potential for clinical application.
METHODS: A retrospective cohort of adult patients with histopathologically confirmed TETs undergoing radical resection between 2015 and 2024 was analyzed. The Kruskal-Wallis test was employed to evaluate associations of systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR) with clinical features (age; gender; myasthenia gravis (MG); World Health Organization (WHO) stage; tumor size; Masaoka stage; WHOMScore). A nomogram diagnostic model was constructed to differentiate thymoma from thymic carcinoma.
RESULTS: A total of 111 patients (52 males, 59 females) were enrolled, including eight cases of type A thymoma, 38 type AB, nine type B1, 16 type B2, 12 type B3, and 28 thymic carcinomas. Correlations between SII, NLR, PLR, and clinicopathological features (gender, age, MG, tumor size, risk stratification, Masaoka stage, and WHO classification) were analyzed. Significant differences in SII, NLR, and PLR were observed across WHO classifications (P SII < 0.001; P NLR < 0.001; P PLR = 0.004). Dunn's test further revealed that these differences primarily stemmed from distinctions between thymoma and thymic carcinoma groups. Based on PLR and MG status, a combined diagnostic model was developed, which demonstrated favorable performance in differentiating thymoma from thymic carcinoma (AUC = 0.804).
CONCLUSION: Our findings suggest that inflammatory biomarkers (SII, NLR, and PLR) are significantly associated with the malignancy of TETs. The combination of PLR and MG status may serve as a useful auxiliary tool for distinguishing thymoma from thymic carcinoma, showing potential for clinical application.